March 3, 2020 09:24 AM ESTUpdated 04:42 PM

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again

Natalie Grover

Reporter

Atlas Venture-backed Unum, which once harbored ambitions to rival the two CAR-T therapies Kymriah and Yescarta, is paying the price for a laundry list of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again

Natalie Grover

Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

House passes Trump tax bill with PBM and orphan drug reforms included

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Fail­ure-prone Unum cuts jobs, los­es sci­en­tif­ic chief, and changes fo­cus yet again

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again